AstraZeneca completes $140M equity investment in Cellectis, a gene-editing therapy biotech.
Cellectis announces the completion of a $140M equity investment by AstraZeneca, initially announced in November 2023. The deal involves AstraZeneca subscribing for 10M class A convertible preferred shares and 18M class B shares in Cellectis, a clinical-stage biotech company focused on gene-editing therapies. The French Ministry of Economy cleared the investment, meeting all conditions for the transaction to close.
May 06, 2024
4 Articles